Tacrolimus

Overview

Tacrolimus is an immunosuppressive drug primarily used to reduce the risk of organ transplant rejection. It acts by inhibiting T-lymphocyte activation.

API suppliers (11)

Suppliers of Tacrolimus backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Biocon LimitedIndia2 active DMF
• CONCORD BIOTECH LTD2 active DMF
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF
• Lek Pharmaceuticals D.D.Slovenia1 active DMF
• CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF
• Lek Pharmaceuticals D.D.Slovenia1 active DMF
• HANGZHOU HUADONG MEDICINE GROUP BIOTECHNOLOGY INSTITUTE CO LTD
• ANTIBIOTICOS SPA
• JOYANG LABORATORIESChina

Patent & exclusivity (US)

Per the FDA Orange Book (58 approved US products), the latest listed US patent on Tacrolimus expires 29 Aug 2028 and exclusivity 15 Jul 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas